Could a custom chemo dose make stem cell transplants safer?
NCT ID NCT05540340
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study tests a new way to calculate the dose of the chemotherapy drug melphalan for lymphoma patients about to receive a stem cell transplant. Instead of a fixed dose based on height and weight, researchers use a model that considers how previous patients processed the drug, aiming to give each person an optimal dose. The goal is to see if this personalized approach can reduce side effects while still being effective.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- melphalan
- What this could lead to
- If successful, this could lead to a safer, more personalized way to dose melphalan for lymphoma patients receiving a stem cell transplant, potentially reducing side effects while maintaining effectiveness.
- What could go wrong
- This is a very early phase 1 study with only 39 participants, so results may not apply to all patients. The personalized dosing method may not work as expected or could still cause significant side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could muscle loss predict blood cancer outcomes?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can engineered immune cells tackle brain lymphoma?
- Talking about the end: could guided conversations reduce futile cancer treatments?
- A simple blood test may reveal hidden infertility risk in young cancer survivors
- Can a targeted pill boost Chemotherapy's punch against lymphoma?